Skip to main content
SpringerLink
Log in

Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Eighteen patients are evaluable for response in a Phase II trial of Mitoxantrone for advanced adenoid cystic carcinoma of the head and neck. One patient had a complete response; there were no partial responses. Twelve patients had stable disease for 3 or more months. There was no significant anti-tumor activity of Mitoxantrone in the group of patients with adenoid cystic carcinoma, all of whom were previously heavily treated with surgery, chemotherapy and/or radiation therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rentschler R, Burgess M, Byers R: Chemotherapy of malignant major salivary gland neoplasms. A 25-year review of the M.D. Anderson Experience. Cancer 4:619–624, 1977

    Google Scholar 

  2. Vermeer RJ, Pinedo HM: Partial remissions of advanced adenoid cystic carcinoma obtained with Adriamycin. A case report with review of the literature. Cancer 43:1604–1606, 1979

    Google Scholar 

  3. de Jager R, Cappelaere P, Earl H, Rubens R, Harris RS, Smith I, Carmichael J, Smythe J, Keiling R, Renard J, van Glabbeke M, Mathe G: Phase II clinical trial of mitoxantrone: 1,4-dihydroxy-5–8-bis(((2-((2-hydroxyethyl)amino)-ethyl)amino)9,10 anthracenedione dihydrochloride in solid tumors and lymphomas. (Abstr) Proc Amer Soc Clin Oncol 1: 89, 1982

    Google Scholar 

  4. Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA Jr: Phase I clinical investigation of l-4-dihydroxy-5,8-bis-(((2-((2-hydroxyethyl)amino)ethyl)amino)9,10 anthracenedi-one dihydrochloride (NSC 301739), a new anthracenedione. Cancer Res 40:1516–1518, 1980

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins Hospital, Baltimore, MD

    Douglas E. Mattox

  2. University of Texas Health Science Center at San Antonio, San Antonio, TX

    Daniel D. Von Hoff

  3. Ohio State University Hospital, Columbus, OH, USA

    Stanley P. Balcerzak

Authors
  1. Douglas E. Mattox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel D. Von Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stanley P. Balcerzak
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Address for offprints: Southwest Oncology Group (SWOG-8030), Operations Office, 5430 Fredericksburg Road, Suite #618, San Antonio, TX 78229, USA

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mattox, D.E., Von Hoff, D.D. & Balcerzak, S.P. Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck. Invest New Drugs 8, 105–107 (1990). https://doi.org/10.1007/BF00216934

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00216934

Key words

Search

Navigation